Our team uses the most sophisticated technology and procedures available to treat
complex cancers of the brain, head, neck, and central nervous system. The Brain Tumor
Center is at the forefront of advances to prolong and improve the quality of life
for patients with every type of malignant brain tumor, including glioblastomas, gliomas,
head and neck tumors, spinal tumors and metastatic tumors.
- Multidisciplinary team: Includes fellowship-trained specialists in neurosurgery, neuro-oncology, neuro-radiology,
radiation oncology, otolaryngology-head and neck surgery, neuro-ophthalmology and
medical oncology We use advanced technology and procedures to treat complex tumors
of the central nervous system, as well as neurologic complications of cancer and its
- Advanced Technology: We utilize the latest treatment tools, including Gamma Knife Perfexion with Extend
technology, which treats brain tumors previously believed inoperable, without an incision.
- Tumor Board: The tumor board is accessible twice a month by affiliated centers in Georgia or non-affiliated
partners. We deliver recommendations for diagnosis and treatment, but also perform
a screening for potential enrollment in our clinical trials.
- Compassionate Care: Our clinical practice is patient- and family-centered. Dedicated resources have been
allocated to offer the strongest support for our brain tumor patients and their families.
A patient helps the patients through the different multimodal steps of their therapy
and during the healing phase of their recovery period. An integrative medicine program
will be launched in fall 2013 with a specific focus on a mind-body approach. It will
include meditation, acupuncture, yoga, reiki, music therapy, hypnosis, aromatherapy,
healing touch, and other supportive-care methods to enhance the efficacy of conventional
therapies and reduce their toxicities.
Clinical Trails and Early Drug development
Our goal is to design innovative clinical trials for patients with brain tumors who
have failed conventional therapy and test new therapeutic hypotheses based on our
three scientific missions: immune modulation, angiogenesis, and cell signaling and
biomarkers. The program, in collaboration with the Experimental Therapeutics Program
at the Cancer Center, is opening clinical trials for primary brain tumors and brain
metastases. For example, recent trials have been initiated to evaluate the role of
front-line vaccines in newly diagnosed GBM, or immune modulators in combinations with
bevacizumab, radiation, or chemotherapy for recurrent GBM.
Basic and Translational Research
Our research program focuses on the molecular mechanisms underlying brain tumors that
have the highest potential to translate into clinically relevant therapies. Our core
facilities have the ability to explore the entire genome of the brain tumors using
next-generation sequencing technology. Current evaluations are underway to explore
the regulation of the EGFR gene in GBM, and to detect circulating blood markers (Detection
of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J. Neurooncol.
2013 Jul 23). Our innovative immunology program has identified new pathways (such
as IDO or Indoleamine 2,3-dioxygenase) that will be evaluated in a clinical intervention
in a GBM trial activated for fall 2013.